{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"groups":[{"description":"Vaginal Cuff Brachytherapy: Clinical stage I-II endometrial cancer surgically staged.\n\nStage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)","id":"OG000","title":"Vaginal Cuff Brachytherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Patients With Progression-free Survival at 2 Years","type":"PRIMARY","unitOfMeasure":"Participants"}